Cure Pharmaceutical
Holding Corp (OTCMKTS:CURR)
impressive start to the year is at risk. The
stock has pulled lower from one-year highs in what appears to be a corrective
phase. A 20% pullback comes, even on the company strengthening its
intellectual patent portfolio.

Cure Price Analysis

The pharmaceutical company is fresh from securing a new patent that details the high loading of the active ingredient in oral thin films. In addition, the company has also secured a patent on oral thin films with Biphasic release of natural ingredients. The announcement of a strategic partnership with Canopy Growth Corp (NYSE:CGC) also went a long way in strengthening the stock’s sentiments in the market prior to the pullback.

The stock’s short-term momentum has turned bearish in recent
weeks as short sellers continue to take the fight to the bulls. As the
stock continues to trade in a downtrend with a bearish bias, immediate support
as part of the correction phase is seen at the $3.20 level.

A sell-off followed by a close below the $3.20 level could give
short sellers a reason to continue pushing CURE Pharmaceutical lower.
Conversely, the stock stabilizing above the $3.20 level could trigger a
bounce-back likely to support further upside action, in continuation of the
long-term uptrend.

Strengthening IP

Amidst the recent price action activity, CURE Pharmaceutical
remains bullish as a long-term play. The strengthening of the patent portfolio
should continue to strengthen investors sentiments in the stock.

The new patent on oral thin films with Bi-Phasic release
should go along way in expanding the pharmaceutical company’s proprietary drug
system CURE film. The patent on high loading of the active ingredient in oral
thin films should also enhance the company’s ability to come up with thin edible
films that can deliver high doses. The new patents also pave the way for the
pharmaceutical company to differentiate its oral thin films for specific drug
opportunities such as cannabidiol.

“With an increased consumer demand for natural wellness products, one of our areas of focus is to improve the delivery plant components and extracts in novel ways. With this patent, we continue to build out our capabilities and IP portfolio around Phyto-actives,” explained CEO Rob Davidson.